In the present study, we compared the ER (ESR1), PR (PGR), and HER2 (ERBB2) status and the resulting subtypes of nearly 400 breast cancer specimens, as determined by the IHC and RT-PCR methods, and then evaluated their corresponding clinical performance in predicting differential breast cancer recurrence. This evidence concerns the gene ERBB2 and breast cancer.